organization · Reporting owner
Column Group LLC
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Oric Pharmaceuticals, Inc.ORIC · Entity 4765 | 10% owner | November 12, 2021 | November 16, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Oric Pharmaceuticals, Inc.
Report date November 12, 2021 · Filed November 16, 2021
Jointly reported with COLUMN GROUP II, LP, Column Group II GP, LP, GOEDDEL DAVID V, Svennilson Peter
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 16,625 |
Reported balance
After 2021-11-12 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-11-12 · Exercise / conversion · Acquired 16,625 · Balance 16,625 F1: These securities are directly held by Peter Svennilson. Peter Svennilson is a former member of the Issuer's board of directors and previously filed his own Section 16 reports reporting his holdings. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 287,702 |
Reported balance
After 2021-11-16 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2021-11-16 · Other · Acquired 287,702 · Balance 287,702 F4: Represents a change in the form of ownership of TCG II GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II LP. F5: The securities are directly held by TCG II GP. The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each individual TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2021-11-16 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2021-11-16 · Other · Disposed 287,702 · Balance 0 F6: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by TCG II GP to its partners. F5: The securities are directly held by TCG II GP. The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each individual TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 86,716 |
Reported balance
After 2021-11-16 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2021-11-16 · Other · Acquired 86,716 · Balance 86,716 F7: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP. F8: These securities are directly held by David Goeddel. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 103,341 |
Reported balance
After 2021-11-16 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2021-11-16 · Other · Acquired 86,716 · Balance 103,341 F9: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP. F1: These securities are directly held by Peter Svennilson. Peter Svennilson is a former member of the Issuer's board of directors and previously filed his own Section 16 reports reporting his holdings. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 74 |
Reported balance
After 2021-11-16 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2021-11-16 · Other · Acquired 74 · Balance 74 F10: Represents a change in the form of ownership of The Column Group, LLC ("TCG LLC") by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP. F11: These securities are directly held by TCG LLC. The managing members of TCG LLC are the TCG II GP Managing Partners and Timothy Kutzkey (collectively, the "TCG LLC Managing Partners"). The TCG LLC Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG LLC and each of the TCG LLC Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
| Common StockSEC Table I · non-derivative | Direct | 3,568,181 |
Reported balance
After 2021-11-16 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2021-11-16 · Other · Disposed 1,200,000 · Balance 3,568,181 F2: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by The Column Group II, LP ("TCG II LP") to its general and limited partners. F3: The securities are directly held by TCG II LP, and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to have voting and investment power with respect to such shares. TCG II GP and each individual TCG II GP Managing Partner disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2031-06-15 | IndirectSee Footnote | 0 |
Reported balance
After 2021-11-12 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-11-12 · Exercise / conversion · Disposed 16,625 · Balance 0 F12: As of the transaction date, 16,625 of the shares subject to this option have vested. F1: These securities are directly held by Peter Svennilson. Peter Svennilson is a former member of the Issuer's board of directors and previously filed his own Section 16 reports reporting his holdings. F13: The option was granted to Peter Svennilson for his service as a member of the Issuer's board of directors. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are directly held by Peter Svennilson. Peter Svennilson is a former member of the Issuer's board of directors and previously filed his own Section 16 reports reporting his holdings.
F2: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by The Column Group II, LP ("TCG II LP") to its general and limited partners.
F3: The securities are directly held by TCG II LP, and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to have voting and investment power with respect to such shares. TCG II GP and each individual TCG II GP Managing Partner disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
F4: Represents a change in the form of ownership of TCG II GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II LP.
F5: The securities are directly held by TCG II GP. The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each individual TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
F6: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by TCG II GP to its partners.
F7: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP.
F8: These securities are directly held by David Goeddel.
F9: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP.
F10: Represents a change in the form of ownership of The Column Group, LLC ("TCG LLC") by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP.
F11: These securities are directly held by TCG LLC. The managing members of TCG LLC are the TCG II GP Managing Partners and Timothy Kutzkey (collectively, the "TCG LLC Managing Partners"). The TCG LLC Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG LLC and each of the TCG LLC Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
F12: As of the transaction date, 16,625 of the shares subject to this option have vested.
F13: The option was granted to Peter Svennilson for his service as a member of the Issuer's board of directors.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
RAPT Therapeutics, Inc.
Report date December 23, 2024 · Filed December 23, 2024
Jointly reported with COLUMN GROUP II, LP, Column Group II GP, LP, PONOI CAPITAL, LP, Ponoi Management, LLC, Ponoi Capital II, LP, Ponoi II Management, LLC, Kutzkey Tim, GOEDDEL DAVID V, Svennilson Peter
Section 16 reporting ended · disclosed 2024-12-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 50,000 |
Reported balance
After 2024-12-23 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-12-23 · Other · Disposed 1,352,008 · Balance 50,000 F1: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F2: The securities are directly held by TCG II LP. The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-12-23 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2024-12-23 · Other · Disposed 1,599,417 · Balance 0 F1: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F3: The securities are directly held by Ponoi LP. Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "Ponoi Managing Partners"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,236,261 |
Reported balance
Holding disclosure · report date 2024-12-23 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,236,261 F4: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "TCG IV Managing Members"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 42,189 |
Reported balance
Holding disclosure · report date 2024-12-23 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 42,189 F5: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 163 |
Reported balance
Holding disclosure · report date 2024-12-23 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 163 F6: The securities are directly held The Column Group LLC ("TCG LLC"). The managing members of TCG LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 145,401 |
Reported balance
Holding disclosure · report date 2024-12-23 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 145,401 F7: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi II LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi II LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
| Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 1,352,008 |
Reported balance
After 2024-12-23 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-12-23 · Other · Acquired 1,352,008 · Balance 1,352,008 F1: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F8: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F2: The securities are directly held by TCG II LP. The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
| Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee footnote | 1,599,417 |
Reported balance
After 2024-12-23 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-12-23 · Other · Acquired 1,599,417 · Balance 1,599,417 F1: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F8: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F3: The securities are directly held by Ponoi LP. Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "Ponoi Managing Partners"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share.
F2: The securities are directly held by TCG II LP. The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
F3: The securities are directly held by Ponoi LP. Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "Ponoi Managing Partners"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
F4: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "TCG IV Managing Members"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F5: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F6: The securities are directly held The Column Group LLC ("TCG LLC"). The managing members of TCG LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
F7: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi II LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi II LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
F8: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 23, 2024 Filed Dec 23, 2024 17:57 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | OtherWarrant (right to purchase) · Derivative | 1,599,417 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000950170-24-139754 · ownership.xml · derivative · entry 8 COLUMN GROUP II, LP · CIK 0001600420 · Former 10% Owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,599,417 Underlying: Common Stock · 1,599,417 shares Expires not disclosed F1 · kind: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F1 · price: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F8 · derivative.exercise_date: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F8 · derivative.expiration_date: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F3 · ownership.nature: The securities are directly held by Ponoi LP. Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "Ponoi Managing Partners"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document |
| December 23, 2024 Filed Dec 23, 2024 17:57 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | OtherWarrant (right to purchase) · Derivative | 1,352,008 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000950170-24-139754 · ownership.xml · derivative · entry 7 COLUMN GROUP II, LP · CIK 0001600420 · Former 10% Owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,352,008 Underlying: Common Stock · 1,352,008 shares Expires not disclosed F1 · kind: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F1 · price: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F8 · derivative.exercise_date: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F8 · derivative.expiration_date: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F2 · ownership.direct: The securities are directly held by TCG II LP. The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document |
| December 23, 2024 Filed Dec 23, 2024 17:57 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | OtherCommon Stock | 1,599,417 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-139754 · ownership.xml · nonDerivative · entry 2 COLUMN GROUP II, LP · CIK 0001600420 · Former 10% Owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F1 · price: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F3 · ownership.nature: The securities are directly held by Ponoi LP. Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "Ponoi Managing Partners"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document |
| December 23, 2024 Filed Dec 23, 2024 17:57 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | OtherCommon Stock | 1,352,008 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-139754 · ownership.xml · nonDerivative · entry 1 COLUMN GROUP II, LP · CIK 0001600420 · Former 10% Owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 F1 · kind: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F1 · price: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F2 · ownership.direct: The securities are directly held by TCG II LP. The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document |
| May 25, 2022 Filed May 27, 2022 16:24 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | PurchaseCommon Stock | 63 | $12.45 | $784.66 |
DisclosureSEC source: 0000899243-22-019937 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 42,189 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.44 to $12.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F3 · ownership.nature: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| May 25, 2022 Filed May 27, 2022 16:24 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | PurchaseCommon Stock | 1,837 | $12.45 | $22,879.65 |
DisclosureSEC source: 0000899243-22-019937 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,236,261 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.44 to $12.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG IV Managing Members"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| May 24, 2022 Filed May 25, 2022 16:19 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | PurchaseCommon Stock | 538 | $12.00 | $6,457.13 |
DisclosureSEC source: 0000899243-22-019470 · doc4.xml · nonDerivative · entry 4 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 42,126 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.605 to $12.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4. F3 · ownership.nature: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| May 24, 2022 Filed May 25, 2022 16:19 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | PurchaseCommon Stock | 15,776 | $12.00 | $189,345.13 |
DisclosureSEC source: 0000899243-22-019470 · doc4.xml · nonDerivative · entry 3 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,234,424 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.605 to $12.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG IV Managing Members"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| May 23, 2022 Filed May 25, 2022 16:19 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | PurchaseCommon Stock | 338 | $12.50 | $4,224.76 |
DisclosureSEC source: 0000899243-22-019470 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 41,588 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.44 to $12.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F3 · ownership.nature: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| May 23, 2022 Filed May 25, 2022 16:19 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | PurchaseCommon Stock | 9,898 | $12.50 | $123,718.07 |
DisclosureSEC source: 0000899243-22-019470 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,218,648 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.44 to $12.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG IV Managing Members"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| May 10, 2022 Filed May 12, 2022 17:28 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | PurchaseCommon Stock | 41,250 | $10.67 | $440,199.38 |
DisclosureSEC source: 0000899243-22-017787 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 41,250 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.55 to $11.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4 F3 · ownership.nature: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| May 10, 2022 Filed May 12, 2022 17:28 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | PurchaseCommon Stock | 1,208,750 | $10.67 | $12,899,175.63 |
DisclosureSEC source: 0000899243-22-017787 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,208,750 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.55 to $11.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2 · ownership.nature: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG IV Managing Members"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| November 16, 2021 Filed Nov 16, 2021 16:49 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | OtherCommon Stock | 74 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-044836 · doc4.xml · nonDerivative · entry 7 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 74 F10 · kind: Represents a change in the form of ownership of The Column Group, LLC ("TCG LLC") by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP. F11 · ownership.nature: These securities are directly held by TCG LLC. The managing members of TCG LLC are the TCG II GP Managing Partners and Timothy Kutzkey (collectively, the "TCG LLC Managing Partners"). The TCG LLC Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG LLC and each of the TCG LLC Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document |
| November 16, 2021 Filed Nov 16, 2021 16:49 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | OtherCommon Stock | 86,716 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-044836 · doc4.xml · nonDerivative · entry 6 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 103,341 F9 · kind: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP. F1 · ownership.nature: These securities are directly held by Peter Svennilson. Peter Svennilson is a former member of the Issuer's board of directors and previously filed his own Section 16 reports reporting his holdings. Read SEC document |
| November 16, 2021 Filed Nov 16, 2021 16:49 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | OtherCommon Stock | 86,716 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-044836 · doc4.xml · nonDerivative · entry 5 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 86,716 F7 · kind: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP. F8 · ownership.nature: These securities are directly held by David Goeddel. Read SEC document |
| November 16, 2021 Filed Nov 16, 2021 16:49 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | OtherCommon Stock | 287,702 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-044836 · doc4.xml · nonDerivative · entry 4 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F6 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by TCG II GP to its partners. F5 · ownership.nature: The securities are directly held by TCG II GP. The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each individual TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document |
| November 16, 2021 Filed Nov 16, 2021 16:49 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | OtherCommon Stock | 287,702 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-044836 · doc4.xml · nonDerivative · entry 3 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 287,702 F4 · kind: Represents a change in the form of ownership of TCG II GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II LP. F5 · ownership.nature: The securities are directly held by TCG II GP. The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each individual TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document |
| November 16, 2021 Filed Nov 16, 2021 16:49 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | OtherCommon Stock | 1,200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-044836 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,568,181 F2 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by The Column Group II, LP ("TCG II LP") to its general and limited partners. F3 · ownership.direct: The securities are directly held by TCG II LP, and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to have voting and investment power with respect to such shares. TCG II GP and each individual TCG II GP Managing Partner disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 16:49 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionStock Option (right to buy) · Derivative | 16,625 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-21-044836 · doc4.xml · derivative · entry 8 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 16,625 shares Expires 2031-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: As of the transaction date, 16,625 of the shares subject to this option have vested. F1 · ownership.nature: These securities are directly held by Peter Svennilson. Peter Svennilson is a former member of the Issuer's board of directors and previously filed his own Section 16 reports reporting his holdings. F13 · ownership.nature: The option was granted to Peter Svennilson for his service as a member of the Issuer's board of directors. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 16:49 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionCommon Stock | 16,625 | $16.00 | $266,000.00 |
DisclosureSEC source: 0000899243-21-044836 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 16,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: These securities are directly held by Peter Svennilson. Peter Svennilson is a former member of the Issuer's board of directors and previously filed his own Section 16 reports reporting his holdings. Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 16:58 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | Exercise / conversionStock Option (Right to Buy) · Derivative | 625 | $0.00 Strike: $19.30 | $0.00 |
DisclosureSEC source: 0000899243-21-038196 · doc4.xml · derivative · entry 13 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,875 Underlying: Common Stock · 625 shares Expires 2031-05-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: As of the transaction date, 625 of the shares subject to this option have vested. F1 · ownership.nature: These securities are directly held by Peter Svennilson. F7 · ownership.nature: The option was granted to Peter Svennilson for his service as a member of the Issuer's board of directors. Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 16:58 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,114 | $0.00 Strike: $22.20 | $0.00 |
DisclosureSEC source: 0000899243-21-038196 · doc4.xml · derivative · entry 12 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,115 Underlying: Common Stock · 1,114 shares Expires 2031-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: As of the transaction date, 1,114 of the shares subject to this option have vested. F1 · ownership.nature: These securities are directly held by Peter Svennilson. F7 · ownership.nature: The option was granted to Peter Svennilson for his service as a member of the Issuer's board of directors. Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 16:58 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $28.27 | $0.00 |
DisclosureSEC source: 0000899243-21-038196 · doc4.xml · derivative · entry 11 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 15,000 Underlying: Common Stock · 7,500 shares Expires 2030-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: As of the transaction date, 7,500 of the shares subject to this option have vested. F1 · ownership.nature: These securities are directly held by Peter Svennilson. F7 · ownership.nature: The option was granted to Peter Svennilson for his service as a member of the Issuer's board of directors. Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 16:58 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | SaleCommon Stock | 625 | $34.94 | $21,840.38 |
DisclosureSEC source: 0000899243-21-038196 · doc4.xml · nonDerivative · entry 6 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · ownership.nature: These securities are directly held by Peter Svennilson. Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 16:58 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | Exercise / conversionCommon Stock | 625 | $19.30 | $12,062.50 |
DisclosureSEC source: 0000899243-21-038196 · doc4.xml · nonDerivative · entry 5 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: These securities are directly held by Peter Svennilson. Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 16:58 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | SaleCommon Stock | 1,114 | $34.97 | $38,951.01 |
DisclosureSEC source: 0000899243-21-038196 · doc4.xml · nonDerivative · entry 4 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · ownership.nature: These securities are directly held by Peter Svennilson. Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 16:58 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | Exercise / conversionCommon Stock | 1,114 | $22.20 | $24,730.80 |
DisclosureSEC source: 0000899243-21-038196 · doc4.xml · nonDerivative · entry 3 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,114 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: These securities are directly held by Peter Svennilson. Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 16:58 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | SaleCommon Stock | 7,500 | $34.48 | $258,606.00 |
DisclosureSEC source: 0000899243-21-038196 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · ownership.nature: These securities are directly held by Peter Svennilson. Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 16:58 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | Exercise / conversionCommon Stock | 7,500 | $28.27 | $212,025.00 |
DisclosureSEC source: 0000899243-21-038196 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: These securities are directly held by Peter Svennilson. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 17:16 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | SaleCommon Stock | 4,720 | $37.70 | $177,957.22 |
DisclosureSEC source: 0000899243-21-036293 · doc4.xml · nonDerivative · entry 13 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F16 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $37.57 to $38.06, inclusive. David Goeddel undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (16) to this Form 4. F6 · ownership.nature: These securities are directly held by David Goeddel. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 17:16 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | SaleCommon Stock | 12,939 | $37.22 | $481,633.57 |
DisclosureSEC source: 0000899243-21-036293 · doc4.xml · nonDerivative · entry 12 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,720 F15 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $36.53 to $37.52, inclusive. David Goeddel undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (15) to this Form 4. F6 · ownership.nature: These securities are directly held by David Goeddel. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 17:16 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | SaleCommon Stock | 4,400 | $37.67 | $165,762.08 |
DisclosureSEC source: 0000899243-21-036293 · doc4.xml · nonDerivative · entry 11 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F14 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $37.53 to $38.06, inclusive. Peter Svennilson undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (14) to this Form 4. F2 · ownership.nature: These securities are directly held by Peter Svennilson. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 17:16 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | SaleCommon Stock | 11,476 | $37.21 | $427,065.57 |
DisclosureSEC source: 0000899243-21-036293 · doc4.xml · nonDerivative · entry 10 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,400 F13 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $36.53 to $37.51, inclusive. Peter Svennilson undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (13) to this Form 4. F2 · ownership.nature: These securities are directly held by Peter Svennilson. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 17:16 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | SaleCommon Stock | 2,926 | $37.31 | $109,157.94 |
DisclosureSEC source: 0000899243-21-036293 · doc4.xml · nonDerivative · entry 9 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F12 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $37.27 to $37.39, inclusive. Tim Kutzkey undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (12) to this Form 4. F10 · ownership.nature: These securities are directly held by Tim Kutzkey. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 17:16 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | SaleCommon Stock | 32,211 | $36.85 | $1,187,065.54 |
DisclosureSEC source: 0000899243-21-036293 · doc4.xml · nonDerivative · entry 8 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,926 F11 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $36.27 to $37.26, inclusive. Tim Kutzkey undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (11) to this Form 4. F10 · ownership.nature: These securities are directly held by Tim Kutzkey. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 17:16 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | SaleCommon Stock | 1,496 | $35.75 | $53,476.91 |
DisclosureSEC source: 0000899243-21-036293 · doc4.xml · nonDerivative · entry 7 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 35,137 F9 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $35.26 to $36.25, inclusive. Tim Kutzkey undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (9) to this Form 4. F10 · ownership.nature: These securities are directly held by Tim Kutzkey. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 17:16 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | SaleCommon Stock | 10,807 | $37.31 | $403,261.04 |
DisclosureSEC source: 0000899243-21-036293 · doc4.xml · nonDerivative · entry 6 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 17,659 F8 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $37.26 to $37.465, inclusive. David Goeddel undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (8) to this Form 4. F6 · ownership.nature: These securities are directly held by David Goeddel. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 17:16 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | SaleCommon Stock | 42,151 | $36.92 | $1,556,046.32 |
DisclosureSEC source: 0000899243-21-036293 · doc4.xml · nonDerivative · entry 5 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 28,466 F7 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $36.26 to $37.255, inclusive. David Goeddel undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (7) to this Form 4. F6 · ownership.nature: These securities are directly held by David Goeddel. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 17:16 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | SaleCommon Stock | 1,700 | $35.77 | $60,814.44 |
DisclosureSEC source: 0000899243-21-036293 · doc4.xml · nonDerivative · entry 4 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 70,617 F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $35.26 to $36.25, inclusive. David Goeddel undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F6 · ownership.nature: These securities are directly held by David Goeddel. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 17:16 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | SaleCommon Stock | 25,351 | $37.27 | $944,844.45 |
DisclosureSEC source: 0000899243-21-036293 · doc4.xml · nonDerivative · entry 3 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 15,876 F4 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $37.18 to $37.50, inclusive. Peter Svennilson undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2 · ownership.nature: These securities are directly held by Peter Svennilson. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 17:16 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | SaleCommon Stock | 29,634 | $36.79 | $1,090,142.99 |
DisclosureSEC source: 0000899243-21-036293 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 41,227 F3 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $36.165 to $37.11, inclusive. Peter Svennilson undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F2 · ownership.nature: These securities are directly held by Peter Svennilson. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 17:16 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | SaleCommon Stock | 1,400 | $35.71 | $49,989.94 |
DisclosureSEC source: 0000899243-21-036293 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 70,861 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $35.15 to $36.09, inclusive. Peter Svennilson undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.nature: These securities are directly held by Peter Svennilson. Read SEC document |
| September 13, 2021 Filed Sep 14, 2021 17:31 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | SaleCommon Stock | 4,788 | $35.28 | $168,942.19 |
DisclosureSEC source: 0000899243-21-035845 · doc4.xml · nonDerivative · entry 13 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 36,633 F17 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $35.00 to $35.68, inclusive. Tim Kutzkey undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (17) to this Form 4. F11 · ownership.nature: These securities are directly held by Tim Kutzkey. Read SEC document |
| September 13, 2021 Filed Sep 14, 2021 17:31 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | SaleCommon Stock | 4,726 | $35.27 | $166,692.16 |
DisclosureSEC source: 0000899243-21-035845 · doc4.xml · nonDerivative · entry 12 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 72,261 F16 · price: 16. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $35.00 to $35.69, inclusive. Peter Svennilson undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (16) to this Form 4. F10 · ownership.nature: These securities are directly held by Peter Svennilson. Read SEC document |
| September 13, 2021 Filed Sep 14, 2021 17:31 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | SaleCommon Stock | 4,803 | $35.25 | $169,308.63 |
DisclosureSEC source: 0000899243-21-035845 · doc4.xml · nonDerivative · entry 11 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 72,317 F15 · price: 15. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $35.00 to $35.65, inclusive. David Goeddel undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (15) to this Form 4. F9 · ownership.nature: These securities are directly held by David Goeddel. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 17:31 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | SaleCommon Stock | 7,231 | $35.19 | $254,494.32 |
DisclosureSEC source: 0000899243-21-035845 · doc4.xml · nonDerivative · entry 10 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 41,421 F14 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $35.00 to $35.69, inclusive. Tim Kutzkey undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (14) to this Form 4. F11 · ownership.nature: These securities are directly held by Tim Kutzkey. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 17:31 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | SaleCommon Stock | 7,320 | $35.19 | $257,572.50 |
DisclosureSEC source: 0000899243-21-035845 · doc4.xml · nonDerivative · entry 9 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 76,987 F13 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $35.00 to $35.68, inclusive. Peter Svennilson undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (13) to this Form 4. F10 · ownership.nature: These securities are directly held by Peter Svennilson. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 17:31 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | SaleCommon Stock | 7,187 | $35.19 | $252,940.00 |
DisclosureSEC source: 0000899243-21-035845 · doc4.xml · nonDerivative · entry 8 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 77,120 F12 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $35.00 to $35.69, inclusive. David Goeddel undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (12) to this Form 4. F9 · ownership.nature: These securities are directly held by David Goeddel. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 17:31 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | OtherCommon Stock | 48,652 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-035845 · doc4.xml · nonDerivative · entry 7 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,652 F8 · kind: Represents a change in the form of ownership of the Ponoi Managing Partners by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP. F11 · ownership.nature: These securities are directly held by Tim Kutzkey. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 17:31 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | OtherCommon Stock | 84,307 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-035845 · doc4.xml · nonDerivative · entry 6 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 84,307 F8 · kind: Represents a change in the form of ownership of the Ponoi Managing Partners by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP. F10 · ownership.nature: These securities are directly held by Peter Svennilson. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.